Keywords: valeant, licenses, canada, rights, xyrem, jazz, pharmaceuticals

Valeant licenses Canada rights to Xyrem

Article | 22 January 2007

Print This

Jazz Pharmaceuticals has signed an agreement licensing the Canadian marketing rights for its oral drug Xyrem (sodium oxybate) to fellow ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in